Progress and challenges in the use of latent HIV-1 reactivating agents

Acta Pharmacologica Sinica

Volumn 36, Issue 8, 2015, Pages 908-916

  Shang, Hong Tao ^a   Ding, Ji Wei ^b   Yu, Shu Ying ^a   Wu, Tao ^a   Zhang, Qiu Li ^a   Liang, Fu Jun ^c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^c BEIJING 302 HOSPITAL   (China)

Author keywords

"shock and kill" strategy; CD4 positive T lymphocytes; disulfram; DNA methyltranserase inhibitors; histone deacetylase inhibitors; HIV infection; HIV reactivating agents; interleukin 7; protein kinase C agonist; virus latency

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE; CYTOKINE; DISULFRAM; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE INHIBITOR; INGENOL B; LATENT HUMAN IMMUNODEFICIENCY VIRUS 1 REACTIVATING AGENT; METHYLTRANSFERASE INHIBITOR; MOCETINOSTAT; PANOBINOSTAT; POSITIVE TRANSCRIPTION ELONGATION FACTOR B ACTIVATOR; PROSTRATIN; PROTEIN KINASE C ACTIVATOR; UNCLASSIFIED DRUG; VORINOSTAT; DNA METHYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT VIRUS INFECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; VIRUS LATENCY; VIRUS REACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CD4+ T LYMPHOCYTE; DRUG EFFECTS; HIV INFECTIONS; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DNA MODIFICATION METHYLASES; HISTONE DEACETYLASE INHIBITORS; HISTONE-LYSINE N-METHYLTRANSFERASE; HIV INFECTIONS; HIV-1; HUMANS; VIRUS LATENCY;

EID: 84938786056     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2015.22     Document Type: Review

References (79)

1. Sluis-Cremer N. The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors. Viruses 2014; 6: 2960-73
2. Liu H, Ma Y, Su Y, Smith MK, Liu Y, Jin Y, et al. Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-Analysis. Clin Infect Dis 2014; 59: 1495-502
3. Waters L, Patterson B, Scourfield A, Hughes A, de Silva S, Gazzard B, et al A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience. Int J STD AIDS 2012; 23: 546-52
4. Zhang Z, Fu J, Zhao Q, He Y, Jin L, Zhang H, et al. Differential restoration of myeloid and plasmacytoid dendritic cells in HIV-1-infected children after treatment with highly active antiretroviral therapy. J Immunol 2006; 176: 5644-51
5. Zhang JY, Zhang Z, Wang X, Fu JL, Yao J, Jiao Y, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-Term nonprogressors. Blood 2007; 109: 4671-8
6. Herrera-Carrillo E, Berkhout B. Potential mechanisms for cell-based gene therapy to treat HIV/AIDS. Expert Opin Ther Targets 2015; 19: 245-63
7. Kent SJ, Reece JC, Petravic J, Martyushev A, Kramski M, De Rose R, et al. The search for an HIV cure: tackling latent infection. Lancet Infect Dis 2013; 13: 614-21
8. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-300
9. Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010; 84: 6425-37
10. Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, et al. Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol 2009; 83: 3078-93
11. Jeeninga RE, Westerhout EM, van Gerven ML, Berkhout B. HIV-1 latency in actively dividing human T cell lines. Retrovirology 2008; 5: 37
12. Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One 2012; 7: e30176
13. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009; 6: 111
14. Marsden MD, Zack JA. Eradication of HIV: current challenges and new directions. J Antimicrob Chemother 2009; 63: 7-10
15. Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology 2013; 10: 11
16. Mbonye U, Karn J. Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res 2011; 9: 554-67
17. Shan L, Yang HC, Rabi SA, Bravo HC, Shroff NS, Irizarry RA, et al. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol 2011; 85: 5384-93
18. Gallastegui E, Millan-Zambrano G, Terme JM, Chavez S, Jordan A. Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J Virol 2011; 85: 3187-202
19. Imai K, Togami H, Okamoto T. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem 2010; 285: 16538-45
20. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1996; 15: 1112-20
21. Chan JK, Greene WC. NF-kappaB/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS 2011; 6: 12-8
22. Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, et al. BET bromodomain-Targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 2013; 12: 452-62
23. Karn J. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS 2011; 6: 4-11
24. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 2007; 26: 412-23
25. Marban C, Redel L, Suzanne S, Van Lint C, Lecestre D, Chasserot-Golaz S, et al. COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells. Nucleic Acids Res 2005; 33: 2318-31
26. Ping YH, Rana TM. DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. J Biol Chem 2001; 276: 12951-8
27. Natarajan M, Schiralli Lester GM, Lee C, Missra A, Wasserman GA, Steffen M, et al. Negative elongation factor (NELF) coordinates RNA polymerase II pausing, premature termination, and chromatin remodeling to regulate HIV transcription. J Biol Chem 2013; 288: 25995-6003
28. Ott M, Geyer M, Zhou Q. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 2011; 10: 426-35
29. Hoque M, Shamanna RA, Guan D, Pe'ery T, Mathews MB. HIV-1 replication and latency are regulated by translational control of cyclin T1. J Mol Biol 2011; 410: 917-32
30. Kim YK, Mbonye U, Hokello J, Karn J. T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. J Mol Biol 2011; 410: 896-916
31. Sadowski I, Lourenco P, Malcolm T. Factors controlling chromatin organization and nucleosome positioning for establishment and maintenance of HIV latency. Curr HIV Res 2008; 6: 286-95
32. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-Treated patients. AIDS 2012; 26: 1473-82
33. Brew BJ, Gray L, Lewin S, Churchill M. Is specific HIV eradication from the brain possible or needed? Expert Opin Biol Ther 2013; 13: 403-9
34. Gray LR, Cowley D, Crespan E, Welsh C, Mackenzie C, Wesselingh SL, et al. Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats. AIDS Res Hum Retroviruses 2013; 29: 365-70
35. Churchill MJ, Cowley DJ, Wesselingh SL, Gorry PR, Gray LR. HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research. J Neurovirol 2015; 21: 290-300
36. Desplats P, Dumaop W, Smith D, Adame A, Everall I, Letendre S, et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 2013; 80: 1415-23
37. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-73
38. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366: 549-55
39. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195: 833-6
40. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008; 22: 1125-9
41. Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008; 22: 1131-5
42. Wightman F, Ellenberg P, Churchill M, Lewin SR. HDAC inhibitors in HIV. Immunol Cell Biol 2012; 90: 47-54
43. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482-5
44. Matalon S, Rasmussen TA, Dinarello CA. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 2011; 17: 466-72
45. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013; 9: 993-1001
46. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 2014; 10: e1004071
47. Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs 2011; 20: 823-9
48. Deeks SG. HIV: Shock and kill. Nature 2012; 487: 439-40
49. Wightman F, Lu HK, Solomon AE, Saleh S, Harman AN, Cunningham AL, et al. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 2013; 27: 2853-62
50. Fenaux P. Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat Clin Pract Oncol 2005; 2: S36-44
51. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009; 5: e1000495
52. Fernandez G, Zeichner SL. Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J 2010; 7: 266
53. du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J 2007; 26: 424-35
54. Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, et al. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol 2011; 85: 9078-89
55. Yamada A, Kataoka T, Nagai K. The fungal metabolite gliotoxin: immunosuppressive activity on CTL-mediated cytotoxicity. Immunol Lett 2000; 71: 27-32
56. Kawahara N, Nozawa K, Yamazaki M, Nakajima S, Kawai K. Structures of novel epipolythiodioxopiperazines, emethallicins B, C, and D, potent inhibitors of histamine release, from Emericella heterothallica. Chem Pharm Bull (Tokyo) 1990; 38: 73-8
57. Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett 2011; 585: 3549-54
58. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009; 8: 1579-88
59. Zayed S, Sorg B, Hecker E. Structure activity relations of polyfunctional diterpenes of the tigliane type, VI. Irritant and tumor promoting activities of semisynthetic mono and diesters of 12-deoxyphorbol. Planta Med 1984; 50: 65-9
60. Szallasi Z, Krsmanovic L, Blumberg PM. Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-Acetate induced tumor promotion in CD-1 mouse skin. Cancer Res 1993; 53: 2507-12
61. Hezareh M, Moukil MA, Szanto I, Pondarzewski M, Mouche S, Cherix N, et al. Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms. Antivir Chem Chemother 2004; 15: 207-22
62. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001; 98: 3006-15
63. Trushin SA, Bren GD, Asin S, Pennington KN, Paya CV, Badley AD. Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol 2005; 79: 9821-30
64. Beans EJ, Fournogerakis D, Gauntlett C, Heumann LV, Kramer R, Marsden MD, et al. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci U S A 2013; 110: 11698-703
65. Jiang G, Mendes EA, Kaiser P, Sankaran-Walters S, Tang Y, Weber MG, et al. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cdelta-NF-kappaB signaling. AIDS 2014; 28: 1555-66
66. Pandelo Jose D, Bartholomeeusen K, da Cunha RD, Abreu CM, Glinski J, da Costa TB, et al. Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology 2014; 462-3: 328-39
67. Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002; 185: 61-8
68. Bowman MC, Archin NM, Margolis DM. Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med 2009; 11: e6
69. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115: 128-37
70. Siegel DS, Zhang X, Feinman R, Teitz T, Zelenetz A, Richon VM, et al. Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. Proc Natl Acad Sci U S A 1998; 95: 162-6
71. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 1996; 93: 5705-8
72. Vlach J, Pitha PM. Hexamethylene bisacetamide activates the human immunodeficiency virus type 1 provirus by an NF-kappa B-independent mechanism. J Gen Virol 1993; 74: 2401-8
73. Choudhary SK, Archin NM, Margolis DM. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4+ T cells. J Infect Dis 2008; 197: 1162-70
74. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-Transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011; 85: 6060-4
75. Doyon G, Zerbato J, Mellors JW, Sluis-Cremer N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS 2013; 27: F7-F11
76. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, et al A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 2014; 58: 883-90
77. Xing S, Bhat S, Shroff NS, Zhang H, Lopez JA, Margolick JB, et al. Novel structurally related compounds reactivate latent HIV-1 in a Bcl-2-Transduced primary CD4+ T cell model without inducing global T cell activation. J Antimicrob Chemother 2012; 67: 398-403
78. Micheva-Viteva S, Kobayashi Y, Edelstein LC, Pacchia AL, Lee HL, Graci JD, et al. High-Throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem 2011; 286: 21083-91
79. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501